Your browser doesn't support javascript.
loading
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters, Solange; Danson, Sarah; Ejedepang, Dunson; Dafni, Urania; Hasan, Baktiar; Radcliffe, Hoi-Shen; Bustin, Frederique; Crequit, Jacky; Coate, Linda; Guillot, Monica; Surmont, Veerle; Rauch, Daniel; Rudzki, Jakob; O'Mahony, Deirdre; Barneto Aranda, Isidoro; Scherz, Amina; Tsourti, Zoi; Roschitzki-Voser, Heidi; Pochesci, Alessia; Demonty, Gaston; Stahel, Rolf A; O'Brien, Mary.
Afiliação
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: Solange.Peters@chuv.ch.
  • Danson S; Department of Oncology and Metabolism & Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom.
  • Ejedepang D; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Dafni U; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.
  • Hasan B; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Radcliffe HS; Amgen Inc, Uxbridge, United Kingdom.
  • Bustin F; Centre Hospitalier Regional De La Citadelle, Liège, Belgium.
  • Crequit J; Centre Hospitalier De Beauvais, France.
  • Coate L; Mid-Western Cancer Centre, University Hospital Limerick, Limerick, Ireland; Cancer Trials, Ireland.
  • Guillot M; Hospital Universitari Son Espases, Palma, Spain; Spanish Lung Cancer Group (GECP), Spain.
  • Surmont V; Universitair Ziekenhuis Gent, Belgium.
  • Rauch D; Spital STS AG Thun, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Switzerland.
  • Rudzki J; Innsbruck Universitaetsklinik, Austria; Central European Cooperative Oncology Group (CECOG), Austria.
  • O'Mahony D; Cork University Hospital, Ireland; Cancer Trials, Ireland.
  • Barneto Aranda I; Hospital Universitario Reina Sofia, Córdoba, Spain; Spanish Lung Cancer Group (GECP), Spain.
  • Scherz A; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Switzerland.
  • Tsourti Z; Frontier Science Foundation-Hellas, Athens, Greece.
  • Roschitzki-Voser H; Coordinating Office, European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Pochesci A; Headquarters, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Demonty G; Amgen NV Diegem, Belgium.
  • Stahel RA; Coordinating Office, European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • O'Brien M; Department of Medical Oncology, Royal Marsden Hospital Sutton, UK.
Lung Cancer ; 161: 76-85, 2021 11.
Article em En | MEDLINE | ID: mdl-34543941
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article